NCT05621707

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)

A Phase 2 Trial of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer . The purpose of this study was to evaluate the efficacy and safety of Concurrent Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Patients With Locally-advanced Esophageal Squamous Cell Cancer.

Conditions

• Esophageal Squamous Cell Carcinomas
• Concurrent Chemoradiotherapy
• Immunotherapy
• Chemotherapy

Interventions

Type	Name	Description
DRUG	chemotherapy combined with PD-1 inhibitors	Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy

Timeline

• Start date: 2022-11-02
• Primary completion: 2026-10-01
• Completion: 2026-10-01
• First posted: 2022-11-18
• Last updated: 2026-02-02

Locations

1 site across 1 country: China